罗芳洪 教授、博士生导师、福建省高层次人才 学科方向：肿瘤学 研究方向：肿瘤靶向治疗 所在系部：抗癌研究中心 办公室：医学院成义楼319-1 办公电话：0592-2180587 电子邮箱：luofanghong@xmu.edu.cn |  |
研究领域
主要从事肿瘤靶向治疗及分子机制研究：（1）纳米药物递送系统靶向联合治疗肿瘤及机制研究；（2）肿瘤光动力/声动力治疗药物研发及分子机制研究；（3）肿瘤靶向单克隆抗体研制及抗肿瘤作用研究。课题组致力于构建制备具有肿瘤靶向和肿瘤微环境响应特性的纳米药物递送系统，以实现基于光动力/声动力的多模式级联肿瘤协同治疗并阐释其作用机制。迄今在Advanced Science，ACS Nano，Theranostics，Chemical Engineering Journal，Advanced Healthcare Materials，ACS Appl. Mater. Interfaces，J Nanobiotechnology，CMGH，JCI Insight等国际学术期刊发表SCI论文50余篇。先后主持国家自然科学基金面上项目、福建省自然科学基金、福建省科技计划项目、厦门市自然科学基金及厦门市科技计划项目共计13项，校企合作项目7项。
学习经历
2006-2013 厦门大学材料学院 高分子化学与物理 博士；
1998-2001 福建医科大学基础医学院 药理学 硕士；
1993-1998 福建医科大学卫生系 预防医学 学士；
工作经历
2025.08-至今 厦门大学医学院抗癌研究中心 教授；
2014.08-2025.07 厦门大学医学院抗癌研究中心 副教授；
2016.03-2017.03 美国梅奥医学中心Mayo Clinic 访问学者/博士后；
2004.08-2014.07 厦门大学医学院抗癌研究中心 助理教授；
2001.08-2004.07 厦门大学抗癌研究中心 助教；
代表性成果
1.Wu YJ#, Zhao ZY#, Ma ML#,Zhang WJ, Liu W, Liang XC, Zhao T, Luo L, Wang YJ, Li MQ, Li TT, Liu C, Luo X, Wang SY, Li WY, Wang H, Li WG, Wu T*, Ke ZH*, Luo FH*. Ultrasound- activated erythrocyte membrane-camouflaged Pt(II) layered double hydroxide enhances PD-1 inhibitor efficacy in triple-negative breast cancer through cGAS-STING pathway-mediated immunogenic cell death. Theranostics. 2025,15(4):1456-1477
2.Wang Z#, Miao FL#, Gu LW#, Zhang RY#, Ma Y, Li Y, Zheng JL, Lin ZH, Gao YL, Huang LY, Shen Y*, Wu T*, Luo FH*, Li WG*.Stimulator of Interferon Genes-Activated Biomimetic Dendritic Cell Nanovaccine as a Chemotherapeutic Booster to Enhance Systemic Fibrosarcoma Treatment. ACS Nano. 2024,18(35): 24219-24235.
3.Li TT, Zhong W, Yang L, Zhao ZY, Wang L, Liu C, Li WY, Lv HY, Wang SY, Yan JH, Wu T*, Song G*, Luo FH*. GIPC1 promotes tumor growth and migration in gastric cancer via activating PDGFR/PI3K/AKT signaling. Oncol Res. 2023,32(2): 361-371
4.Zhao ZY, Wu YJ, Liang XC, Liu JJ, Li TT, Liu C, Luo X,Wang YJ, Wang SY, Wu T, Zhang SL, Yang D, Li WG, Yan JH, Ke ZH,* Luo FH*. Sonodynamic Therapy of NRP2 Monoclonal Antibody-Guided MOFs@COF Targeted Disruption of Mitochondrial and Endoplasmic Reticulum Homeostasis to Induce Autophagy-Dependent Ferroptosis. Adv Sci, 2023,10(30):e2303872
5.Zhao ZY, Liu JJ, Wu YJ, Liang XC, Li TT, Wang YJ, Wang SY, Song G, Wu T, Yang D, Yan JH, Li Y*, Wang PY*, Zhong LB*, Luo FH*. Ultrasound-Driven Nanoreactor with USP39 ShRNAi-Intensified Ferroptosis for Synergistic Sono-Chemodynamic Therapy. Chem Eng J. 2023,(471): 144154
6.Liu JJ, Li MQ, Zhao ZY, Luo X, Wang L, Li TT, Liu C, Wang SY, Wu T, Yang D, Li Y,* Wang PY,* Yan JH*, Luo FH*. GSH-responsive and O2-economizing virus-like nanocapsule for photothermal-augmented sonodynamic therapy. Chem Eng J. 2023,(458): 141427
7.Li MQ, Liu JJ, Luo X, Zhao ZY, Wang SY, Liu ZJL, Li TT, Yang D, Li Y*, Wang PY*, Luo FH*, Yan JH*. Monoclonal Antibody-Guided Tumour-Targeted Hollow Virus-Like Cerium Oxide with Oxygen Self-Supply for Intensifying Photodynamic Therapy. Adv Healthc Mater. 2023, 12(8): e2202418
8.Xie F#, Liu ZJL#, Wang PY#, Cai MM, Li Y*, Yan JH*, Lin Q*, Luo FH*. Self-delivery nanodrugs developed via small-molecule-directed assembly and macrophage cloaking for sonodynamic-augmented immunotherapy. Adv Healthc Mater. 2022,11(16):e2102770
9.Wang LL#, Wang L#, Zhang Y, Zhao ZY, Liu C, Li MQ, Liu JJ, Wang SY, Yang D, Luo FH,* Yan JH*. LS-HB-Mediated Photodynamic Therapy Inhibits Proliferation andInduces Cell Apoptosis in Melanoma. Mol Pharm. 2022,19(7):2607-2619
10.Wang L#, Wang LL#, Xu PL#, Liu C, Wang SY, Luo X, Li MQ, Liu JJ, Zhao ZY, Lai WS, Luo FH*, Yan JH*. pH-Responsive Liposomes Loaded with Targeting Procoagulant Proteins as Potential Embolic Agents for Solid Tumor-Targeted Therapy. Mol Pharm. 2022,19(5):1356-1367
11.Liu ZJL#, Wang PY#, Xie F#, Chen JH, Cai MM, Li Y*, Yan JH*, Lin Q*, Luo FH*. Virus-Inspired Hollow Mesoporous Gadolinium-Bismuth Nanotheranostics for Magnetic Resonance Imaging-Guided Synergistic Photodynamic- Radiotherapy. Adv Healthc Mater. 2022,11(6):e2102060
12.Luo X, Xie J, Zhou ZL, Ma SH, Wang L, Li MQ, Liu JJ, Wang PY*, Li Y*, Luo FH*, Yan JH*. Virus-Inspired Gold Nanorod-Mesoporous Silica Core−Shell Nanoparticles Integrated with tTF-EG3287 for Synergetic Tumor Photothermal Therapy and Selective Therapy for Vascular Thrombosis. ACS Appl. Mater. Interfaces. 2021,13(37):44013-44027
13.Liu ZJL#, Xie F#, Xie J, Chen JH, Li Y, Lin Q*, Luo FH*, Yan JH*. New-generation photosensitizer-anchored gold nanorods for a single near-infrared light-triggered targeted photodynamic-photothermal therapy. Drug Deliv. 2021,28(1):1769-1784
14.Xie J#, Zhou ZL#, Ma SH, Luo X, Liu JJ, Wang SY, Chen YQ*, Yan JH*, Luo FH*. Facile Fabrication of BiF3: Ln (Ln = Gd, Yb, Er)@PVP Nanoparticles for High-Efficiency Computed Tomography Imaging. Nanoscale Res Lett. 2021,16(1):131
15.Wang L#, Wang LL#, Wang SY, Zhou ZL, Liu ZJL, Xu PL, Luo X, Wu T*, Luo FH*, Yan JH*. N2E4, a monoclonal antibody targeting neuropilin-2, inhibits tumor growth and metastasis in pancreatic ductal adenocarcinoma via suppressing FAK/Erk/HIF-1α signaling. Front Oncol. 2021,11(7) :657008
16.Zhou ZL#, Xie J# , Ma SH, Luo X, Liu JJ, Wang SY, Chen YQ*, Yan JH*, Luo FH*. Construction of Smart Nanotheranostic Platform Bi-Ag@PVP: Multimodal CT/PA Imaging-Guided PDT/PTT for Cancer Therapy. ACS Omega. 2021,6(16):10723- 10734
17.Li WY#, Liu C#, Huang ZL, Shi L, Zhong CQ, Zhou WW, Meng PP, Li ZY, Wang, SY, Luo FH*, Yan JH*, Wu T*. AKR1B10 negatively regulates autophagy through reducing GAPDH upon glucose starvation in colon cancer. J Cell Sci. 2021,134(8):jcs255273
18.Yaqoob U#, Luo FH#, Greuter T, Jalan-Sakrikar N, Sehrawat T, Hu X, Gao JH, Kostallari E, Arab JP, Cao S*, Shah V*. GIPC-regulated IGFBP-3 promotes HSC migration in vitro and portal hypertension in vivo through a β1-integrin pathway. Cell Mol Gastroenterol Hepatol. 2020,10(3):545-559
19.Liu C#, Wu T#, Wang SY, Zhou WW, Li YX, Chen XL, Li WY, Huang ZL, Li TT, Yang L, Xu PL, Liu ZJL, Xie J, Yang D, Yan JH*, Luo FH*. Anticancer effect of LS-HB-mediated photodynamic therapy on hepatocellular carcinoma in vitro and in vivo. Photodiagnosis Photodyn Ther. 2020, 30(6): 101718
20.Li T#, Lv H#, Yang L, Xie J, Liu C, Xu P, Li W, Wang S, Yang D, Wu T*, Yan J*, Luo F*.Pharmacokinetics and Tissue Distribution of DVDMS-2 in Tumor-bearing Mice. Photochem Photobiol. 2020,96(1):148-155 .
21.Luo FH, Fan ZX, Yin W, Yang L, Li TT, Zhong LB, Li Y, Wang SY, Yan JH, Hou ZQ*, Zhang QQ*. pH-responsive stearic acid-O-carboxymethyl chitosan assemblies as carriers delivering small molecular drug for chemotherapy. Mater Sci Eng C Mater Biol Appl. 2019,105(12):110107.
22.Zhang H, Li Y, Pan Z, Chen Y, Fan Z, Tian H, Zhou S, Zhang Y, Shang J, Jiang B, Wang F, Luo F*, Hou Z*. Multifunctional nanosystem based on graphene oxide for synergesitic multistage tumor-targeting and combined chemo-photothermal therapy. Mol Pharm. 2019,16(5):1982-1998
23.Zou MY, Malik S, Xu PL, Wang SY, Wu T, Luo FH*, Yan JH*. Construction of Novel Procoagulant Protein Targeting Neuropilin-1 on Tumor Vasculature for Tumor Embolization Therapy. J Drug Target. 2019.27(8): 885-895
24.Wu SC#,Yang XR#, Luo FH*, Wu T, Xu PL, Zou MY, Yan JH*. Biosynthesis of flower-shaped Au nanoclusters with EGCG and their application for drug delivery. J Nanobiotechnology. 2018,16(1):90
26.Li Y#, Lin JY#, Ma JY, Song L, Lin HR, Tang BW, Chen DY, Su GH, Ye SF, Zhu X, Luo FH*, Hou ZQ*. Methotrexate-Camptothecin Prodrug Nanoassemblies as a Versatile Nanoplatform for Biomodal Imaging-Guided Self-Active Targeted and Synergistic Chemotherapy. ACS Appl. Mater. Interfaces. 2017, 9 (40): 34650 –34665
27.Hou ZQ, Lin JY, Li YX, Guo FQ, Yu F, Wu HJ, Fan ZX, Zhi LL*, Luo FH*. Validation of a dual role of methotrexate-based chitosan nanoparticles in vivo. RSC Adv. 2015, 52(5):41393-41400
28.Lin JY#, Li YX# , Li Y#, Cui F, Yu F, Wu HJ, Xie LY, Luo, FH*, Hou ZQ*, Lin CJ. Self-targeted, bacillus-shaped, and controlled-release methotrexate prodrug polymeric nanoparticles for intratumoral administration with improved therapeutic efficacy in tumor-bearing mice. J Mater Chem B. 2015,3(39): 7707 -7717
29.Luo FH#, Li Y#, Jia MM, Cui F, Wu HJ, Yu F, Lin JY, Yang XR, Hou ZQ*, Zhang QQ*. Validation of a Janus role of methotrexate-based PEGylated chitosan nanoparticles in vitro. Nanoscale Res Lett, 2014, 9(1):363-375
30.Zeng FW#, Luo FH#, Lv S, Zhang HP, Cao C, Chen XL, Wang SY, Li Z, Wang XJ, Dou XF, Dai YJ, He MJ, Zhang YF, Lv HY, Yan JH*, Chen YQ*. A monoclonal antibody targeting neuropilin-1 inhibits the adhesion of breast cancer cell MCF7 to fibronectin by suppressing FAK/p130cas signaling pathway. Anticancer Drugs. 2014,25(6):663-72
31.Chen XL, Lv HY, Ye M, Wang SY, Ni ER, Zeng FW, Cao C, Luo FH*, Yan JH*. Novel superparamagnetic iron oxide nanoparticles for tumor embolization application: Preparation, characterization and double targeting. Int J Pharm. 2012,426(1-2):248-255
32.Li X#, luo FH#, Wang SY, Ni ER, Tang XY, Lv HY, ChenXL, Chen LK, Yan JH*. A Monoclonal Antibody Against NRP1 b1b2. Hybridoma. 2011,30(4): 369-373
授权专利
1.颜江华，王生育，罗芳洪，吴婷，王勇军，一种葡聚糖的夹心酶联免疫吸附测定方法，专利号，ZL201510513781.9
2.颜江华，王生育，罗芳洪，吴婷，倪二茹，王勇军，抗人神经纤毛蛋白1的单域抗体及其制备方法，专利号，ZL201510757571.4
承担的主要研究项目
1.福建省科技计划项目，仿生纳米反应器调控乳酸代谢增强声动力/免疫治疗三阴性乳腺癌及机制研究，2026R11010033-3，2026-01至2028-12，主持；
2.福建省科技计划项目，介孔聚多巴胺载药纳米颗粒介导声动力及光热效应靶向联合治疗肿瘤研究，2023R1001002，2023-01至2025-07，主持；
3.厦门市自然科学基金项目，GIPC1上调PDGFRβ促进胃癌细胞增殖迁移及其分子机制研究，3502Z20227307，2022-07至2025-06，主持；
4.福建省科技计划项目，新型光敏剂光动力抗肿瘤及作用机制研究，2020R1001001，2020-08至2022-07，主持；
5.福建省科技计划项目，GIPC促进肝癌细胞黏附迁移及其作用机制研究，2017R1036-3，2017-01至2019-12，主持；
6.国家自然科学基金面上项目，NRP-1介导PI3K/AKT信号通路调控乳腺癌淋巴管生成和转移的机制研究，81472458，2015-01至2018-12，主持；
7.厦门市科技计划项目，抗NRP-1功能性抗体的研制及抗肿瘤作用研究，2015-01至2017-12，主持；
8.福建省科技计划项目，抗SEMA3FC单克隆抗体制备及ELISA检测方法建立，2014R1036-4，2014-01至2016-12，主持；
9.福建省自然科学基金，NRP-1单抗介导智能纳米载药系统研制及靶向治疗肝癌研究，2013J01384，2013-01至2015-12，主持；
获奖及荣誉
1.厦门大学科研类奖教金（闽都奖），2024年
2.厦门市高层次人才（C类），2022年
3.福建省高层次人才（C类），2021年
4.厦门大学优秀共产党员，2020年
5.福建省科学技术进步二等奖，2019年
6.福建医学科技奖二等奖，2018年
7.厦门市科学技术进步二等奖，2018年
8.福建省科学技术进步三等奖，2017年
承担课程
本科生课程：药理学，疾病发生与药物治疗基础，呼吸系统，内分泌与生殖系统，机能学实验等；
研究生课程：高级药理学，科研设计与论文写作指导等。
